Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$1.06
-1.9%
$1.39
$0.42
$2.05
$1.05B2.391.75 million shs565,527 shs
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$4.08
-3.1%
$5.74
$1.61
$7.45
$1.08B1.91.55 million shs3.87 million shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$4.16
-1.2%
$5.13
$4.03
$9.06
$857.58M1.93.31 million shs2.73 million shs
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$0.76
-6.1%
$1.91
$0.67
$3.33
$74.97M0.382.81 million shs1.07 million shs
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-1.85%+17.99%-30.26%+45.21%-22.06%
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-3.09%-15.00%-33.87%-31.31%+148.78%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-1.19%-7.56%-16.97%-23.53%-45.41%
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-5.95%+2.80%-70.48%-72.20%-67.88%
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%+2.72%+301.29%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
1.1042 of 5 stars
2.53.00.00.02.30.80.6
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
3.0068 of 5 stars
3.44.00.00.01.93.30.6
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.3863 of 5 stars
3.50.00.04.21.71.70.6
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
1.9572 of 5 stars
3.51.00.00.03.90.80.6
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
1.9162 of 5 stars
2.20.00.04.72.04.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
1.00
Sell$2.50135.85% Upside
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
2.80
Moderate Buy$8.16100.00% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.00
Buy$13.83232.53% Upside
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
3.00
Buy$6.33728.43% Upside
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
2.33
Hold$27.2518.43% Upside

Current Analyst Ratings

Latest AUTL, HARP, GRTS, ADAP, and BCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
4/10/2024
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
4/9/2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $11.00
4/2/2024
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$4.00 ➝ $5.00
3/26/2024
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/18/2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
3/14/2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
3/6/2024
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
2/28/2024
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMkt Outperform$4.00
2/26/2024
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00
2/12/2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$60.28M17.48N/AN/A$0.04 per share26.50
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$1.70M638.97N/AN/A$0.64 per share6.38
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$331.41M2.59N/AN/A($2.22) per share-1.87
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$1.33M56.33N/AN/A$0.54 per share1.42
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$113.87M-$0.55N/AN/AN/A-188.90%-155.39%-43.42%5/10/2024 (Estimated)
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$208.38M-$1.19N/AN/AN/AN/A-105.75%-49.25%5/14/2024 (Confirmed)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$226.54M-$1.18N/AN/AN/A-68.36%N/A-36.96%5/6/2024 (Confirmed)
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$138.49M-$1.20N/AN/AN/A-847.24%-147.22%-69.46%5/9/2024 (Estimated)
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A

Latest AUTL, HARP, GRTS, ADAP, and BCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$0.10N/A+$0.10N/AN/AN/A  
5/6/2024N/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$0.22N/A+$0.22N/AN/AN/A  
3/14/2024Q4 2023
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$0.26-$0.44-$0.18-$0.44N/AN/A
3/6/2024Q4 2023
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$0.12-$0.24-$0.12-$0.24$4.80 million$0.23 million
3/5/2024Q4 2023
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$0.36-$0.26+$0.10-$0.26$4.80 million$10.38 million
2/26/2024Q4 2023
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$0.24-$0.28-$0.04-$0.25$89.19 million$93.40 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/A
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
N/A
2.85
2.85
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/A
6.15
6.15
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
3.31
3.12
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
0.77
3.20
3.20
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
449994.21 million870.53 millionOptionable
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
463265.93 million197.58 millionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
536206.15 million197.08 millionOptionable
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
23198.07 million93.55 millionOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable

AUTL, HARP, GRTS, ADAP, and BCRX Headlines

SourceHeadline
Merck raises 2024 profit forecast on surging sales of cancer drug KeytrudaMerck raises 2024 profit forecast on surging sales of cancer drug Keytruda
msn.com - April 25 at 6:50 PM
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and CompaniesPatented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies
biospace.com - April 15 at 2:25 AM
HARP Apr 2024 20.000 putHARP Apr 2024 20.000 put
finance.yahoo.com - March 16 at 7:49 AM
HARP Sep 2024 20.000 putHARP Sep 2024 20.000 put
finance.yahoo.com - March 16 at 7:49 AM
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)
markets.businessinsider.com - March 13 at 1:51 PM
Merck concludes acquisition of Harpoon TherapeuticsMerck concludes acquisition of Harpoon Therapeutics
medicaldialogues.in - March 13 at 8:50 AM
Merck completes acquisition of Harpoon TherapeuticsMerck completes acquisition of Harpoon Therapeutics
msn.com - March 12 at 2:54 PM
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Buys $492,135,715.00 in StockHarpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Buys $492,135,715.00 in Stock
insidertrades.com - March 12 at 4:24 AM
Merck Acquires Harpoon TherapeuticsMerck Acquires Harpoon Therapeutics
powderbulksolids.com - March 11 at 2:21 PM
Merck closes $650M Harpoon acquisitionMerck closes $650M Harpoon acquisition
njbiz.com - March 11 at 2:21 PM
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
markets.businessinsider.com - March 7 at 5:11 PM
Harpoon Hit With Investor Lawsuit for $680 Million Sale to MerckHarpoon Hit With Investor Lawsuit for $680 Million Sale to Merck
news.bloomberglaw.com - March 7 at 5:11 PM
Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to MerckHarpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck
msn.com - March 6 at 5:40 PM
Janux plans $200m offer on back of prostate cancer readoutJanux plans $200m offer on back of prostate cancer readout
pharmaphorum.com - February 28 at 10:33 AM
Citigroup Downgrades Harpoon Therapeutics (HARP)Citigroup Downgrades Harpoon Therapeutics (HARP)
msn.com - February 27 at 6:09 PM
Analyst Scoreboard: 4 Ratings For Harpoon TherapeuticsAnalyst Scoreboard: 4 Ratings For Harpoon Therapeutics
markets.businessinsider.com - February 26 at 5:08 PM
Harpoon Therapeutics just downgraded at Citi, heres whyHarpoon Therapeutics just downgraded at Citi, here's why
realmoney.thestreet.com - February 24 at 3:43 AM
Fate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers SayFate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers Say
usnews.com - February 23 at 7:05 AM
Merck wins EU backing for Keytruda use in resectable lung cancerMerck wins EU backing for Keytruda use in resectable lung cancer
msn.com - February 23 at 7:05 AM
HARPOON THERAPEUTICS (5HTA.BE)HARPOON THERAPEUTICS (5HTA.BE)
finance.yahoo.com - February 23 at 7:05 AM
Harpoon Therapeutics Inc. (5HTA.SG)Harpoon Therapeutics Inc. (5HTA.SG)
finance.yahoo.com - February 23 at 7:05 AM
Stock (HARP), Short Interest ReportStock (HARP), Short Interest Report
benzinga.com - February 22 at 9:05 PM
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)
markets.businessinsider.com - February 13 at 10:04 AM
Merck notches surprise Q4 profits as Roche miss hampers healthy guidanceMerck notches surprise Q4 profits as Roche miss hampers healthy guidance
mmm-online.com - February 1 at 5:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Adaptimmune Therapeutics logo

Adaptimmune Therapeutics

NASDAQ:ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Autolus Therapeutics logo

Autolus Therapeutics

NASDAQ:AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
BioCryst Pharmaceuticals logo

BioCryst Pharmaceuticals

NASDAQ:BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Gritstone bio logo

Gritstone bio

NASDAQ:GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Harpoon Therapeutics logo

Harpoon Therapeutics

NASDAQ:HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.